Protease inhibitors

Protease inhibitors are a class of antiviral medications commonly used in the treatment of HIV/AIDS and other viral infections such as the hepatitis C virus (HCV). These drugs are a cornerstone of antiretroviral therapy (ART), often combined with nucleoside reverse transcriptase inhibitors and other antiretroviral agents to effectively suppress viral replication. This helps reduce viral load, improve immune function, and prevent HIV-related complications.

Protease inhibitors are antiviral drugs that work through the inhibition of viral proteases, enzymes that are critical for viral replication. In HIV treatment, these medications specifically target HIV-1 protease, a serine protease responsible for cleaving viral polyproteins into functional proteins required for virus assembly. By interfering with this process, protease inhibitors prevent the virus from producing mature, infectious viral particles.

Protease inhibitors are also used for other viral infections, including HCV, where viral proteases play a similar role in viral replication.

Protease inhibitors work by binding to the active site of the viral protease enzyme. This prevents the enzyme from cleaving viral polyprotein precursors into their functional proteins. Without this cleavage, the virus cannot assemble new infectious particles, effectively halting viral replication.

Some protease inhibitors, such as ritonavir, are used in lower doses to boost the levels of other antiretroviral drugs by inhibiting liver enzymes that metabolize the medications. This increases the effectiveness of the treatment while maintaining safer dosing levels. Protease inhibitors are designed to target the viral protease without significantly affecting human cellular enzymes, although some off-target effects may occur, including effects on lipid metabolism and liver function.

Protease inhibitors are a class of antiviral medications commonly used in the treatment of HIV/AIDS and other viral infections such as the hepatitis C virus (HCV). These drugs are a cornerstone of antiretroviral therapy (ART), often combined with nucleoside reverse transcriptase inhibitors and other antiretroviral agents to effectively suppress viral replication. This helps reduce viral load, improve immune function, and prevent HIV-related complications.Common HIV protease inhibitors include:

• Darunavir (Prezista)
• Atazanavir (Reyataz)
• Indinavir (Crixivan)
• Nelfinavir (Viracept)
• Lopinavir/ritonavir (Kaletra)
• Saquinavir (Invirase)
• Tipranavir (Aptivus)
• Fosamprenavir (Lexiva)

Common HCV protease inhibitors include:

• Simeprevir (Olysio)
• Grazoprevir (Zepatier – combined with elbasvir)
• Glecaprevir (Mavyret – combined with pibrentasvir)
• Paritaprevir (Viekira Pak – boosted with ritonavir)
• Voxilaprevir (Vosevi – combined with sofosbuvir/velpatasvir)

Each medication has unique pharmacokinetics, metabolic pathways, and drug interaction profiles. Some are more commonly used as first-line therapy, while others are reserved for patients with drug resistance or intolerance to other protease inhibitors.

Protease inhibitors can also be co-formulated with other antiretroviral agents to simplify dosing and improve adherence to therapy.

Protease inhibitors are primarily used in the treatment and prevention of HIV infection. Their main applications include:

-Treatment of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS)

• Reducing the risk of HIV-related opportunistic infections
• Prophylaxis in high-risk populations to prevent HIV infection
• Treatment of hepatitis C (HCV)

By effectively reducing viral load, protease inhibitors help improve immune function, decrease the risk of HIV progression, and enhance quality of life for patients.

Common side effects may include:

• Nausea and vomiting
• Diarrhea
• Abdominal pain
• Headache
• Fatigue

Metabolic and lipid-related side effects:

• Increased cholesterol and triglycerides
• Lipodystrophy (changes in fat distribution)
• Insulin resistance or hyperglycemia

Other potential effects:

• Liver toxicity
• Kidney stones (indinavir)
• Rare allergic reactions

Long-term use may lead to changes in body fat distribution and cholesterol metabolism, which requires regular monitoring in clinical practice.

These are not all of the possible side effects of Protease Inhibitors. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Although these medications are generally well-tolerated and safe, there are certain warnings, precautions, and drug interactions you should be aware of.

Warnings

Before starting protease inhibitors, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including if you have:

• Liver disease or hepatitis C virus (HCV) co-infection
• High cholesterol or triglycerides
• Diabetes or insulin resistance
• Kidney disease or a history of kidney stones
• Cardiovascular disease or hypertension

Boxed Warning

Some protease inhibitors may carry warnings about serious liver toxicity (including fatal liver failure), increased bleeding risk in hemophiliacs, pancreatitis, and metabolic issues (high cholesterol/triglycerides).

Contraindications

• Known hypersensitivity to any component of the drug formulation
• Concomitant use with certain drugs that are highly dependent on CYP3A metabolism
• Severe hepatic impairment in select medications

Drug interactions

When protease inhibitors are taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

• Other antiretroviral drugs, such as reverse transcriptase inhibitors
• Statins and other cholesterol-lowering medications
• Certain antifungal agents
• St. John’s Wort and herbal supplements
• Drugs metabolized by CYP3A enzymes

Careful monitoring and dose adjustments are often required to avoid toxicity or reduced effectiveness.